U.S. Degenerative Disc Disease Treatment Market
- 2026 年市場規模
- USD 3.52 Mn
- 2033 年預估規模
- USD 5.26 Mn
- 年複合成長率 CAGR
- 5.9%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
U.S. Degenerative Disc Disease Treatment Market, By Treatment Type (Epidural Steroid Injections, Narcotics (Morphine, Methadone Hydrochloride, Codeine, Hydrocodone, Tramodol, Oxycodone, Others), Orthobiologics (Phase I, Phase II, Phase III)), By Disease Indication (Early Stage, Mid Stage, Late Stage), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (U.S.)
報告摘要
Degenerative disc disease refers to symptoms of back or neck pain caused by wear-and-tear on a spinal disc. In some cases, degenerative disc disease also cause weakness, numbness, and hot shooting pains in the arms or legs (radicular pain). Degenerative disc disease typically consists of a low-level chronic pain with intermittent episodes of more severe pain. Degenerative disc diseases are very frequent and debilitating disorders, and R&D activities surrounding this disease are highly cost intensive. Hence, many fund raising companies and manufacturers are engaged in raising funds for their research regarding the treatment of degenerative disc diseases. Depending upon the level of pain, degenerative disc disease can be treated with two common processes which are non-surgical and spinal fusion. Non-surgical treatments include medications, physical therapy, and chiropractic care. Whereas, spinal fusion is a procedure used to surgically treat degenerative disc disease.
Market Dynamics
Key players in the market are focused on growth strategies such as product launch and approval which is expected to drive the growth of market over forecast period. For instance, in April 2021, Cerapedics Inc. an ortho-biologics company, announced that the U.S. Food and Drug Administration (FDA) granted breakthrough device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD). Moreover, in February 2019, FibroGenesis, a company focused on regrowth of the spinal disc nucleus using its universal donor product CybroCell, announced that the U.S. FDA had cleared its investigational new drug (IND) protocol of CybroCell for human trials in the U.S., considered to be the first IND approval for a fibroblast cell therapy in a chronic condition of degenerative disc disease.
Key features of the study
• This report provides in-depth analysis of the U.S. degenerative disc disease treatment market, and provides market size (Mn patients) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. degenerative disc disease treatment market based on the following parameters – company highlights, financial overview, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include AnGes Inc., Ankasa Regenerative Therapeutics, Inc., BIOPHARM GMBH, BioRestorative Therapies Inc., Biosplice Therapeutics, Inc., Bone Therapeutics SA, Cerapedics Inc, CO.DON, Creative Medical Technology Holdings, Inc., DiscGenics Inc., Eli Lilly and Company, Ferring Pharmaceuticals, FibroGenesis, Geistlich Pharma AG, Harbor View Medical Services, PC, Intralink-Spine, Inc., Isto Biologics, Johnson & Johnson, Kolon TissueGene Inc., Kunovus, Lineage Cell Therapeutics, Inc., Mesoblast, NC Biomatrix BV, Notogen Inc., Pfizer, Inc., R3 Stem Cell, Smith & Nephew, Spine BioPharma, Stayble Therapeutics AB, US Stem Cell Inc., and VIVEX Biologics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. degenerative disc disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. degenerative disc disease treatment market
Market Segmentation
• By Treatment Type (Revenue, USD Mn, 2021-2033)
o Epidural Steroid Injections
o Narcotics
Morphine
Methadone Hydrochloride
Codeine
Hydrocodone
Tramodol
Oxycodone
Others
o Orthobiologics
Phase I
Phase II
Phase III
• By Disease Indication (Revenue, USD Mn, 2021-2033)
o Early Stage
o Mid Stage
o Late Stage
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Key Players
o AnGes Inc.
o Ankasa Regenerative Therapeutics, Inc.
o BIOPHARM GMBH
o BioRestorative Therapies Inc.
o Biosplice Therapeutics, Inc.
o Bone Therapeutics SA
o Cerapedics Inc, CO.DON
o Creative Medical Technology Holdings, Inc.
o DiscGenics Inc.
o Eli Lilly and Company
o Ferring Pharmaceuticals
o FibroGenesis
o Geistlich Pharma AG
o Harbor View Medical Services, PC
o Intralink-Spine, Inc.
o Isto Biologics
o Johnson & Johnson
o Kolon TissueGene Inc.
o Kunovus
o Lineage Cell Therapeutics, Inc.
o Mesoblast
o NC Biomatrix BV
o Notogen Inc.
o Pfizer, Inc.
o R3 Stem Cell
o Smith & Nephew
o Spine BioPharma
o Stayble Therapeutics AB
o US Stem Cell Inc.
o VIVEX Biologics, Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Treatment Type
Market Snapshot, By Disease Indication
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global U.S. Degenerative Disc Disease Treatment Market, By Treatment Type, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Epidural Steroid Injections
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Narcotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Morphine
o Methadone Hydrochloride
o Codeine
o Hydrocodone
o Tramodol
o Oxycodone
o Others
o Orthobiologics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Phase I
o Phase II
o Phase III
5. Global U.S. Degenerative Disc Disease Treatment Market, By Disease Indication, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Early Stage
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Mid Stage
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Late Stage
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
6. Global U.S. Degenerative Disc Disease Treatment Market, By Distribution Channel, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
AnGes Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Ankasa Regenerative Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
BIOPHARM GMBH
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
BioRestorative Therapies Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Biosplice Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bone Therapeutics SA
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Cerapedics Inc, CO.DON
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Creative Medical Technology Holdings, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
DiscGenics Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Eli Lilly and Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Ferring Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
FibroGenesis
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Geistlich Pharma AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Harbor View Medical Services, PC
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Intralink-Spine, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Isto Biologics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Johnson & Johnson
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Kolon TissueGene Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Kunovus
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Lineage Cell Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Mesoblast
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
NC Biomatrix BV
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Notogen Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
R3 Stem Cell
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Smith & Nephew
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Spine BioPharma
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Stayble Therapeutics AB
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
US Stem Cell Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
VIVEX Biologics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們